192 related articles for article (PubMed ID: 11659482)
21. NIH guidelines for research involving recombinant DNA molecules.
Wilson DJ
Account Res; 1993; 3(2-3):177-85. PubMed ID: 11652293
[No Abstract] [Full Text] [Related]
22. American guidance for institutional review boards.
Bull Med Ethics; 1998 Nov; No. 143():20-4. PubMed ID: 11657619
[No Abstract] [Full Text] [Related]
23. Testing drugs in pediatric populations: the FDA mandate.
Tauer CA
Account Res; 1999; 7(1):37-58. PubMed ID: 11657562
[No Abstract] [Full Text] [Related]
24. Balancing moral principles in federal regulations on human research.
Ackerman TF
IRB; 1992; 14(1):1-6. PubMed ID: 11652041
[No Abstract] [Full Text] [Related]
25. Institutional review boards and research on individuals with mental disorders.
Hoppe SK
Account Res; 1996; 4(3-4):187-95. PubMed ID: 11654514
[No Abstract] [Full Text] [Related]
26. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern.
Gordon B; Prentice E
IRB; 1997; 19(2):8-11. PubMed ID: 11655323
[No Abstract] [Full Text] [Related]
27. The NIH report of its review of the Baby Fae case.
Dommel FW;
IRB; 1986; 8(2):1-4. PubMed ID: 11649748
[No Abstract] [Full Text] [Related]
28. Federal investigation concludes that institutional review boards are in trouble.
Maloney DM
Hum Res Rep; 1998 Aug; 13(8):1-2. PubMed ID: 11657190
[No Abstract] [Full Text] [Related]
29. Eyeing a project's ethics.
Stone R
Science; 1993 Mar; 259(5103):1820. PubMed ID: 11643255
[No Abstract] [Full Text] [Related]
30. Growth hormone trials to contine.
Stone R
Science; 1993 Feb; 259(5097):883. PubMed ID: 11643254
[No Abstract] [Full Text] [Related]
31. If it's research, it must be reviewed: an NIH reprimand.
Levine C
Hastings Cent Rep; 1986 Feb; 16(1):2-3. PubMed ID: 11643913
[No Abstract] [Full Text] [Related]
32. Institutional animal care and use committees.
Britt DP
ATLA Abstr; 1986 Mar; 13(3):236-9. PubMed ID: 11649839
[No Abstract] [Full Text] [Related]
33. Multicenter trials and subject eligibility: should local IRBs play a role?
Freedman B
IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
[No Abstract] [Full Text] [Related]
34. IRBs and randomized clinical trials.
Meinert CL
IRB; 1998; 20(2-3):9-12. PubMed ID: 11656915
[No Abstract] [Full Text] [Related]
35. Protection of human subjects.
United States
Code Fed Regul Shipping; 1982 Oct; Part 46, Sections 46.101 to 46.306():. PubMed ID: 11660819
[No Abstract] [Full Text] [Related]
36. The NIH inclusion guidelines: challenges for the future.
Rothenberg KH; Hayunga EG; Rudick JE; Pinn VW
IRB; 1996; 18(3):1-4, 12. PubMed ID: 11654407
[No Abstract] [Full Text] [Related]
37. Safety boards must report their conclusions to IRBs.
Maloney DM
Hum Res Rep; 1999 Oct; 14(10):3. PubMed ID: 11658061
[No Abstract] [Full Text] [Related]
38. Commission says institutional review boards should change procedures now.
Maloney DM
Hum Res Rep; 1999 Jan; 14(1):1-2. PubMed ID: 11657555
[No Abstract] [Full Text] [Related]
39. Conflict at the RAC.
Culliton BJ
Science; 1990 Apr; 298(4952):159. PubMed ID: 11653881
[No Abstract] [Full Text] [Related]
40. IRBs and pharmaceutical company funding of research.
Jellinek MS; Levine RJ
IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
